ClinicalTrials.gg
RecruitingNCT05336201Updated Feb 27, 2026

Cognitive Remediation Intervention to Prepare for Transition of Care

A Phase 2 interventional study of CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) in Sickle Cell Disease, Cognitive Impairment and Adolescent Behavior, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University of Alabama at Birmingham · Phase 2, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Study summary

Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.

Read the detailed description

Cognitive impairment is a pervasive debilitating feature of sickle cell disease (SCD), with over 50% of children demonstrating early neurodevelopmental delays, ultimately influencing ability for adolescents with SCD to engage in effective decision-making needed for successful transition into adulthood. The negative effect of cognitive impairment on transition to adult self-care is further compounded by health-related disparities and poor social determinants of health. Transition to self-care among youth with SCD may be facilitated by cognitive remediation. One potential avenue to disseminate cognitive-based interventions to disadvantaged neighborhoods is through telehealth administration. This study will examine the efficacy of C-READY on adaptive and self-management skills in youth with SCD, where there is a critical need to enhance self-efficacy/self-care skills for successful transition into adulthood. Additionally, this study overcomes the barriers of transportation that preclude vulnerable patient populations from returning to the clinic for in-person interventions by offering the intervention in their homes via telehealth. C-READY is a manualized, individualized intervention delivered over the course of 4 weeks in 8, 60 minute one-on-one telehealth sessions between the youth and trained therapist. Caregiver involvement and accountability is promoted by weekly phone sessions in between the 8 primary sessions. The emphasis C-READY is on promotion of independence with adaptive skills necessary for transition of care to adult healthcare, such as managing medications, pain management, sleep hygiene, and/or daily health-related routines; the objective is to identify and focus on goals that best promote those skills. Thus, we will conduct a two-arm, wait-listed randomized control trial among 120 patients with SCD (ages 10-18 years), 60 participants per group; half randomized to the intervention arm, and half to the waitlist arm. The primary outcome is transition readiness skills, with secondary outcome measures of cognitive abilities and neuroimaging metrics. We hypothesize that youth with SCD who participate in C-READY will show improvement in transition readiness skills and show greater improvement in cognitive performance. We also hypothesize that participation in C-READY will improve functional brain connectivity and increase compensatory neural mechanisms. In sum, this study will be the first step in developing highly accessible and scalable evidence-based intervention to improve transition of care, enhance self-care, and ultimately improve overall quality of life in youth with SCD.

02

Conditions studied

  • Sickle Cell Disease
  • Cognitive Impairment
  • Adolescent Behavior
  • Self Efficacy
  • Health-Related Behavior
  • Coping Skills
03

In context

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

This study's planned enrollment of 120 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.

Browse Anemia, Sickle Cell studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SCD (all genotypes)
  • Active follow-up at Children's of Alabama Hospital
  • Ages 10-18
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • History of seizures or overt stroke
  • History of Intellectual Disability or Autism Spectrum Disorder
  • Inability to participate in the MRI scan, such as metal implants, neurostimulators, claustrophobia
  • Currently on psychotropic medications
05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    C-READY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)

    Self-management and goal-setting cognitive remediation

    Behavioral: CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)

  • Other
    Wait-List Control Group

    Will receive the same C-READY intervention after a 4-week wait period

    Behavioral: CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)

Interventions

  • BehavioralCREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)

    Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.

06

What researchers measure

Primary outcomes

  1. Transition Readiness

    Questionnaire assessing how knowledgeable the youth is about their health condition and the skills necessary for self-management and self-advocacy

    Time frame: 4-weeks

  2. Transition Readiness

    Questionnaire assessing how knowledgeable the youth is about their health condition and the skills necessary for self-management and self-advocacy

    Time frame: 4-months post-intervention

Secondary outcomes

  1. Cognitive Assessment

    A global cognitive deficit score will be calculated that assesses intellectual functioning, working memory, processing speed, attention, language, and executive functioning. The global cognitive deficit score is calculated as an average of test scores and normalized to a scale of 0-5, with 0 indicating normal functioning and 5 indicating severe deficits.

    Time frame: 4-weeks

  2. Cognitive Assessment

    A global cognitive deficit score will be calculated that assesses intellectual functioning, working memory, processing speed, attention, language, and executive functioning. The global cognitive deficit score is calculated as an average of test scores and normalized to a scale of 0-5, with 0 indicating normal functioning and 5 indicating severe deficits.

    Time frame: 4-months post-intervention

  3. Neuroimaging

    Brain scan (MRI) of structural and functional connectivity

    Time frame: 4-weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Sharing of the data generated by this project is an essential part of our proposed activities and will be carried out in several different ways. We will also make our results available to other scientists interested in understanding cognitive outcomes in youth with sickle cell disease, and to avoid unintentional duplication of research. We also hope that the results of this study will lead to future collaboration to further develop approaches to improve transition of care outcomes in adolescents and youth adults with sickle cell disease. Our plan includes presentation at national and international meetings and publications in peer-reviewed medical journals. All publications of these data will contain a statement of data sharing so that other researchers will know of its availability.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Sep 2026, 50 months after the start.

Of 58 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 50 months is close to that.

Counting every sponsor, half of 92 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 20, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Sep 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05336201
Responsible party
Donna Murdaugh (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Apr 20, 2022
Start date
Jul 1, 2022
Primary completion
Sep 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Donna Murdaugh, PhD
Contact
donnamurdaugh@uabmc.edu
2056382189

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion